Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Device: RT-CGMDevice: SMBG
- Registration Number
- NCT06591286
- Lead Sponsor
- Shanghai 6th People's Hospital
- Brief Summary
Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.
- Detailed Description
Glycemic management of patients with diabetes after discharge home is extremely challenging, especially for those requiring insulin therapy. The use of a real-time continuous glucose monitoring (RT-CGM) system may improve glycemic control and self-efficacy in patients with type 2 diabetes treated with insulin after discharge from the hospital.
One hundred and fifty insulin-treated adults with type 2 diabetes were randomly assigned to receive either RT-CGM or self-monitoring of blood glucose (SMBG) at hospital discharge for a 12-week monitoring intervention and a 36-week follow-up.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- 18 years old ≤ age ≤ 80 years old.
- Type 2 diabetes admitted to Department of Endocrinology and Metabolism.
- 8% ≤ HbA1c ≤ 12% in the last 1 month.
- Insulin therapy within 1 month of planned discharge from hospital.
- Frequency of self-monitoring of blood glucose <4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation.
- Willing and able to provide written informed consent and comply with the requirements of this study.
-
Oral steroid hormone therapy.
-
Any of the following cardiovascular diseases within the last 6 months.
- Myocardial infarction.
- Cardiac surgery or haemodialysis (coronary artery bypass grafting/percutaneous transluminal coronary angioplasty).
-
Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis)
-
Patients with severe liver disease (alanine aminotransferase or glutamine aminotransferase exceeding more than three times the upper limit of normal).
-
Patients with severe kidney injury or end-stage renal disease (eGFR < 30 mL/min/1.73 m2).
-
Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
-
Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
-
Pregnant, breastfeeding, women of childbearing age who are unwilling to use contraception during the study period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention group RT-CGM The intervention group (75 cases) will wear real-time CGM to monitor blood glucose for 12 weeks, followed by 36 weeks of follow-up. Control group SMBG The control group (75 cases) is self-monitored by traditional SMBG for 12 weeks at a frequency of no less than 4 times a week, followed by 36 weeks of follow-up.
- Primary Outcome Measures
Name Time Method Time in range (3.9~10.0mmol/L, %) 12 weeks Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM.
- Secondary Outcome Measures
Name Time Method HbA1c (%) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Glycated hemoglobin (%)
Time in range (3.9~10.0mmol/L, %) 4weeks, 8weeks, 24weeks, 48 weeks Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM.
Time above range (>10.0mmol/L, %) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Percentage of time above glucose level of 10.0 mmol/L (180 mg/dL) measured by CGM.
Time below range (<3.9mmol/L, %) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM.
Coefficient of variation (CV) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Standard deviation divided by mean glucose level measured by CGM.
Standard deviation (SD) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Standard deviation of blood glucose measurements during CGM.
Mean amplitude of glycemic excursions (MAGE) 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks Mean amplitude of glycemic excursions (MAGE) is the average value of all amplitude of glycemic excursions.
Diabetes management self-efficacy 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks The Chinese version of Diabetes Management Self-efficacy Scale (DMSES) is used to evaluate the patients' self-efficacy
Diabetes Self Care Activities 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks The Chinese version of Summary of Diabetes Self Care Activities (SDSCA) is used to evaluate the patients' self-efficacy
Trial Locations
- Locations (1)
Shanghai 6th People's Hospital
🇨🇳Shanghai, Shanghai, China